Giardia lamblia antibody and antigen (recombinant protein)

Diagnostic anti-Giardia lamblia antibodies pairs and antigen for animal health (animal Cat/Feline, Dog/Canine, Rabbit, Bovines/Cattle, Equine/Horse, Ovines/Sheep, Caprine/Goat, Fish, Swine/Porcine/Pig, Avian/Bird/Poultry infectious disease Giardiasis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Multiple species disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P264-Ag01 Recombinant Giardia lamblia protein $3090.00
GMP-VT-P264-Ab01 Anti-Giardia lamblia mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P264-Ab02 Anti-Giardia lamblia mouse monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P264-Ag01
Product Name Recombinant Giardia lamblia protein
Pathogen Giardia lamblia
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Giardia lamblia antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Giardia lamblia level test of animal Cat/Feline, Dog/Canine, Rabbit, Bovines/Cattle, Equine/Horse, Ovines/Sheep, Caprine/Goat, Fish, Swine/Porcine/Pig, Avian/Bird/Poultry infectious disease with Giardiasis.
Tag His
Product description Recombinant Giardia lamblia proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P264-Ab01,GMP-VT-P264-Ab02
Pathogen Giardia lamblia
Product Name Anti-Giardia lamblia mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Giardia lamblia antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Giardia lamblia antibodies in Giardia lamblia level test of animal Cat/Feline, Dog/Canine, Rabbit, Bovines/Cattle, Equine/Horse, Ovines/Sheep, Caprine/Goat, Fish, Swine/Porcine/Pig, Avian/Bird/Poultry infectious disease with Giardiasis.
Product description Anti-Giardia lamblia mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Giardia lamblia antibodies./td>
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Pathogen


    Giardia lamblia, also known as Giardia intestinalis or Giardia duodenalis, is a flagellated protozoan parasite that can cause giardiasis, an intestinal illness characterized by symptoms such as abdominal cramps, flatulence, and intermittent diarrhea. In humans, the infection is prevalent in developing countries and can occur sporadically in developed countries. The pathogen is transmitted through the fecal-oral route, usually via contaminated water or food sources.

    The genetic makeup of Giardia lamblia is unique in the sense that it lacks traditional mitochondrial DNA (mtDNA) and instead possesses highly derived mitochondria-related organelles (MROs). Unlike conventional mtDNA, the MROs have a circular genome, which contains genes encoding enzymes required for ATP generation and electron transport. Furthermore, the genome of Giardia lamblia contains a high proportion of genes corresponding to variant surface proteins (VSPs), which allow the parasite to rapidly change its surface antigens and evade host immune responses.

    Giardia lamblia typically exists in two forms: a vegetative trophozoite form and an infectious cyst form. The trophozoite form is the active feeding and reproducing form, while the cyst form is resistant to harsh environmental conditions and is responsible for the transmission of the infection. The cyst form is shed in feces and can survive in water or soil for months. When ingested, the cysts release trophozoites in the small intestine, where they attach to the intestinal lining and reproduce via binary fission.

    In addition to humans, Giardia lamblia has a diverse range of hosts, including domestic and wild animals such as dogs, cats, cattle, sheep, and beavers. Infection with Giardia lamblia in animals can result in symptoms similar to those observed in humans. In particular, beavers are considered a key reservoir for the parasite, and their activities in water sources may increase the risk of human exposure.

    The diagnosis of Giardia lamblia is usually based on clinical symptoms and laboratory analysis of stool samples. Microscopic examination of fresh or stained stool specimens can help identify the presence of cysts or trophozoites. Alternatively, antigen detection assays such as enzyme-linked immunosorbent assay (ELISA) can detect the presence of Giardia-specific antigens in stool samples. Nucleic acid-based detection methods such as polymerase chain reaction (PCR) can also be used to amplify and detect Giardia lamblia DNA from stool samples. PCR-based detection commonly targets the 18S rRNA gene, although other gene targets such as the triosephosphate isomerase (tpi) gene and glutamate dehydrogenase (gdh) gene have also been utilized.

    The treatment of giardiasis typically involves the use of antibiotics such as metronidazole or nitazoxanide. However, the emergence of drug-resistant strains of Giardia lamblia has been reported, highlighting the need for continued efforts to develop new therapeutic options. Furthermore, because of the potential for waterborne transmission, measures to improve water and food safety are critical in preventing and controlling giardiasis outbreaks.

    In conclusion, Giardia lamblia is a unique and complex protozoan parasite that can cause giardiasis, a diarrheal illness that affects millions of people worldwide. The genetic makeup of Giardia lamblia, including the absence of traditional mtDNA and the abundance of VSPs, allow the parasite to evade host immune responses and adapt to changing environmental conditions. Continued research efforts are needed to better understand the pathogenesis and transmission of giardiasis and to develop effective preventive and therapeutic strategies.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.